Most Read Articles
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Oral Xa inhibitors prevent recurrent venous thromboembolism in cancer patients

12 Oct 2018

Oral factor Xa inhibitors may be used as potential substitutes for warfarin and low molecular weight heparin for the prevention of recurrent thromboembolism in oncology patients, suggests a recent study. However, randomized controlled trials are warranted to confirm these results.

A total of 127 patients with venous thromboembolism were recruited, of whom 48 received rivaroxaban or apixaban, 23 received enoxaparin, and 56 received warfarin. Lung (21 percent), colorectal (14 percent) and breast (14 percent) were the three most common cancer diagnoses.

At 3 months, no difference was observed between the rivaroxaban/apixaban (0 percent), warfarin (3.6 percent) and the enoxaparin cohorts (4.4 percent; p=0.8319). Only one patient in the enoxaparin arm (4.2 percent) had a major bleeding at 3 months.

Moreover, mortality was 0 percent, 3.6 percent and 17.4 percent in the rivaroxaban/apixaban, warfarin and enoxaparin cohorts, respectively, at 3 months.

In another study, Xing and colleagues found that rivaroxaban was on a par with enoxaparin in terms of safety and efficacy for the prevention of recurrent venous thromboembolism in patients with malignancy, indicating rivaroxaban as a potential option for cancer patients with venous thromboembolism. [Medicine (Baltimore) 2018;97:e11384]

In this study, the authors used retrospectively obtained data to compare the recurrent venous thromboembolism incidence in oncology patients taking rivaroxaban/apixaban, enoxaparin or warfarin with at least 3 months of follow-up. Inclusion criteria for patients were as follows: active cancer, venous thromboembolism, and taking warfarin, enoxaparin or rivaroxaban/apixaban.

The first episode of recurrent venous thromboembolism at 3 months was the primary endpoint, while the secondary endpoints included recurrent venous thromboembolism after 6 months, major bleeding and mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
24 Aug 2016

Roshini Claire Anthony spoke with Adjunct Associate Professor Gamaliel Tan, head and senior orthopaedic consultant at Ng Teng Fong Hospital in Singapore, on how GPs can help diagnose and treat lower back pain.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.